The company was incorporated as Syngene International Private Limited on November 18, 1993 at Bengaluru, Karnataka as a private limited company under the Companies Act, 1956. Pursuant to a special resolution of the shareholders dated March 26, 2007, the company was converted into a public limited company and the name of the company was changed to Syngene International Limited. A fresh certificate of incorporation consequent upon conversion to public limited company was issued on April 19, 2007. The company was promoted by Kiran Mazumdar Shaw, a promoter of Biocon. On March 30, 2002, 99.9 per cent of the Equity Shares of the company were transferred to Biocon and as a result, the company became the subsidiary of Biocon.
The company is one of the leading India-based contract research organisations (CRO), offering a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. Its service offerings in discovery and development cover multiple domains across small molecules, large molecules, antibody-drug conjugates (ADC) and oligonucleotides. Its integrated discovery and development platforms help organisations conduct discovery (from hit to candidate selection), development (including pre-clinical and clinical studies, analytical and bio-analytical evaluation, formulation development and stability studies) and pilot manufacturing (scale-up, pre-clinical and clinical supplies) under one roof with a distinctive economic advantage. The company’s service offerings also support the development of bio-similar and generic molecules. In the near term, it intends to forward integrate into commercial-scale manufacturing of NMEs.
As an experienced CRO with a proven track record of providing quality NME discovery, development and manufacturing services and continued focus on reliability, responsiveness and protection of client’s intellectual property, the company is well-positioned to benefit from the expected growth in the CRO industry. It offers an attractive variable cost alternative to the traditionally fixed cost, in-house, resource intensive business model of R&D focussed organisations.
Business area of the company
It offers services through flexible business models that are customised to its clients’ requirements. These range from a full-time equivalent (FTE) to a fee-for-service (FFS) model, or a combination thereof. During fiscal 2015, it serviced 221 clients, ranging from multinational corporations to start-ups, including eight of the top 10 global pharmaceutical companies by sales for 2014. The company has several long-term relationships and multi-year contracts with its clients, including three long-duration multi-disciplinary partnerships, each with a dedicated research centre, with three of the world’s leading global healthcare organisations Bristol-Myers Squibb Co. (BMS), Abbott Laboratories (Singapore) and Baxter International Inc.